Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

NCT02647944 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide helps with weight loss and affects how quickly the stomach empties food in adults with obesity.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 40 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2015-12 · est. completion 2016-12

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT02647944 ↗

Description as written by the study sponsor.

This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.

Treatments tested

Liraglutide also known as Saxenda Drug

Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (\~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
Placebo Drug

Main thing measured	Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks
Sponsor	Mayo Clinic
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02647944 ↗